Pfizer’s COVID-19 vaccine trial data shows long-term efficacy

Pfizer’s COVID-19 vaccine
Pfizer said on Monday its COVID-19 vaccine provided strong long-term protection against the virus in a late-stage study conducted among adolescents aged 12 to 15 years.

A two-dose series of the vaccine was 100% effective against COVID-19, measured seven days through over four months after the second dose, the company said.

The long-term data will support planned submissions for full-regulatory approval of the vaccine in the age group in the United States and worldwide.

Pfizer and BioNTech will seek clearance for a 30 micrograms dose of the vaccine for those aged 12 and above.

The vaccine was authorized for emergency use in people aged 12-15 years by the U.S. Food & Drug Administration in May, and granted full approval for use in people aged 16 and above in August.



from latest-news - SUCH TV https://ift.tt/3FFnxyl

Comments

Popular posts from this blog

Six more die in rain-related incidents in Karachi

Low payments by fed govt hampered development in Sindh, CM Murad tells Bilawal Bhutto

Four soldiers martyred in gun battle with terrorists in North Waziristan: ISPR

Saudi princess freed after three years in jail

Joint Opposition to move no-confidence motion against NA Speaker Asad Qaiser

Former PM's close aide Shahzad Akbar's name placed on ECL

CPEC extend to Afghanistan says China

New on Sports Illustrated: Forde-Yard Dash: The SEC is Unrecognizable as Defenses Underwhelm

Pakistan rejects illegal grant of IOK domicile certificates to Indians

Taliban declare war in Afghanistan over, call for peaceful relations with world